Navigation Links
Cytopia To Present Data on FMS Program With Anticancer Potential
Date:6/17/2008

MELBOURNE, Australia, June 18 /PRNewswire/ -- Cytopia Limited (ASX: CYT) will present details of its FMS drug discovery and development program at the Protein Kinase Targets conference, a leading conference for breakthrough scientific data on new kinase inhibitory drugs. This conference will be held from 23 to 25 June in Boston, USA.

This is the first scientific disclosure of data from the Cytopia FMS program and will be presented by Cytopia Senior Scientist Dr Michael Harte. Dr Harte's presentation is scheduled for 3:15 pm (US EDT) 25 June.

The presentation will describe the potent activity of a series of compounds discovered at Cytopia. These compounds inhibit the function of macrophages, key cells in the immune system and mediators of inflammatory reactions. As such these compounds have therapeutic potential in treating conditions such as rheumatoid arthritis. The inhibition of cells that are responsible for bone osteolysis in advanced cancer disease is also part of the physiological potential of FMS inhibitors.

Preliminary data on the potential of Cytopia's potent FMS inhibitors to treat advanced cancer in in vivo models will also be presented at this conference.

Cytopia CEO Mr Andrew Macdonald said, "We are very encouraged by the excellent preclinical profile of these compounds. This first public disclosure of our work raises the profile of this program to the broader scientific community and reflects the excellent science undertaken by the team."

This presentation is in the same month that Cytopia presented its CYT997 cancer findings to ASCO, the world's biggest oncology conference held in Chicago.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules with an improved therapeutic profile for the treatment of cancer. Cytopia's lead compound, CYT997, is currently in Phase II clinical trials.

Website: http://www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cytopia Commences Phase II Cancer Drug Study
2. Gentiva(R) Health Services to Present June 24 at Jefferies 2nd Annual Healthcare Conference in New York
3. Parks Associates Analysts Present Insights on Broadband, Digital Content, Advertising, Home Systems, and Digital Health at CONNECTIONS(TM)
4. Emageon to Present at the Jefferies 2nd Annual Healthcare Conference
5. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia
6. VNUS Medical Technologies to Present at William Blair & Companys 28th Annual Growth Stock Conference
7. WebMD to Present at the William Blair 28th Annual Growth Stock Conference
8. Cardiva Medical, Inc. to Present at the Investment In Innovation (In3) Medical Device Summit on June 18, 2008 in San Francisco, CA; Announces the Completion of Its Latest Phase in Its US Sales Force Expansion
9. Digirad Corporation to Present at CapStone Small-Cap Investor Conference
10. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
11. EntreMed to Present at the BIO 2008 Annual International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... Getting enough sleep affects much more than energy ... going just 19 hours without sleep can compromise motor reaction time, which can increase the ... Amica Insurance is sharing the following tips from the NSF to help you sleep better ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April ... of Urgent Care Medicine will host industry leaders for the annual spring Convention ... those in the industry adapt to the issues currently affecting urgent care and ...
(Date:4/28/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, has published a new post that ... Yisrayl says with so many titles and names for the Creator, it’s hard for many ... Scripture, backed with a lot of research, the truth is undeniable. , “If you ...
(Date:4/28/2017)... York, New York (PRWEB) , ... April 28, ... ... high-quality anti-aging skincare and advanced nutraceutical supplements, through its Nova Skin ... cream provides the hydrating benefits of a moisturizer with the power of an ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
(Date:4/18/2017)... April 18, 2017 Viverae ® , a ... the integration of IBM ® Watson Campaign Automation, ... targeted communications for a personalized experience. Through digital engagement, ... their health in real time. The enhanced experience drives ... to members, wherever they are in their journey to ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
Breaking Medicine Technology: